Fairmount Healthcare Fund II L.P. 4

What Happened
Fairmount Funds Management LLC (reported as a director) was granted a derivative award on 2026-05-27: an option representing the right to purchase 8,026 shares of Spyre Therapeutics common stock. The Form 4 reports the acquisition at $0.00 (no cash paid) and a reported value of $0. The option vests and becomes fully exercisable on the earlier of May 27, 2027 or the Issuer’s 2027 annual meeting, subject to continuous service by Tomas Kiselak.

Key Details

• Transaction date: 2026-05-27 (Form 4 filed 2026-05-29; appears timely).
• Transaction type/code: Grant/Award (derivative) — option to purchase 8,026 shares.
• Price/consideration: $0.00 (reported). Reported dollar amount: $0.
• Shares owned after transaction: not specified in the filing.
• Footnote F1: Vesting on earlier of 5/27/2027 or 2027 annual meeting, contingent on continuous service by Tomas Kiselak.
• Footnote F2: Tomas Kiselak holds the option for one or more investment vehicles managed by Fairmount (the Adviser) and will turn over any net cash or stock to the Adviser for the benefit of those funds; he disclaims beneficial ownership except to the extent of his pecuniary interest.
• Remark: The Adviser and Fairmount Healthcare Fund II L.P. may be deemed directors by deputization because Tomas Kiselak serves on Spyre’s board and is Managing Member of the Adviser.

Context
This is an equity award (a derivative grant), not an immediate purchase, sale, or exercise — no shares were sold or cashed out in this filing. Director awards like this are commonly used as compensation and do not necessarily indicate near-term trading intentions. The option is held for investment vehicles managed by the Adviser, so beneficial ownership is attributed to those funds rather than to Mr. Kiselak personally.